Abstract
Combination antiplatelet therapy with clopidogrel and aspirin is routine following coronary artery stenting. Worldwide, more than 2 million people undergo this procedure each year, making clopidogrel the second most prescribed drug in the world (over US$9 billion in sales in 2010).1 There is considerable inter-individual variability in platelet response to clopidogrel, which means that patients with a low response are at a significant risk of thromboembolic complications, such as fatal stent thrombosis.2 Therefore, identifying factors that influence clopidogrel efficacy is crucial.
Original language | English |
---|---|
Pages (from-to) | 14-16 |
Number of pages | 3 |
Journal | Journal of Pharmacy Practice and Research |
Volume | 41 |
Issue number | 1 |
DOIs | |
Publication status | Published - Mar 2011 |
Bibliographical note
Copyright:Copyright 2017 Elsevier B.V., All rights reserved.